Canine Leptospirosis: Clinical Presentation, Serovar Epidemiology, and Rapid Diagnostic Strategies

Introduction

Canine leptospirosis is a globally distributed zoonotic bacterial disease caused by pathogenic spirochetes of the genus Leptospira. The infection primarily affects the renal and hepatic systems, leading to acute kidney injury, hepatopathy, and vascular inflammation [1, 2]. Over the past two decades, shifts in serovar prevalence have been documented across numerous geographic regions, accompanied by an expansion of the host range [3, 4]. Concurrently, advancements in molecular diagnostics have improved the speed and accuracy of antemortem detection, particularly through the use of real-time PCR and immunochromatographic assays [5, 6]. This review provides an exhaustive examination of the clinical spectrum, serovar epidemiology, and diagnostic approaches for canine leptospirosis, with emphasis on the comparative utility of the microscopic agglutination test (MAT) versus PCR-based methods and the principles of vaccination.

Bacteriology and Pathogenesis

Leptospira are obligate aerobic, motile, Gram-negative spirochetes belonging to the phylum Spirochaetes. Pathogenic species are classified within the Leptospira interrogans sensu lato group, which includes over 250 serovars organized into serogroups based on lipopolysaccharide (LPS) antigenicity [7]. The outer membrane is composed of LPS, lipoproteins, and transmembrane porins that mediate adhesion to host extracellular matrix components [8, 9]. After penetration through mucous membranes or abraded skin, leptospires disseminate hematogenously and evade the alternative complement pathway through recruitment of factor H and C4b-binding protein [10, 11]. The organisms colonize the proximal renal tubules, where they adhere to the apical surface of tubular epithelial cells via fibronectin-binding proteins [12]. Chronic renal carriage in recovered dogs can result in persistent urinary shedding, serving as a source of environmental contamination [13].

The host inflammatory response involves Toll-like receptor 2 (TLR2) and TLR4 recognition of leptospiral glycolipids, triggering the release of proinflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 [14, 15]. In severe cases, endothelial injury leads to vasculitis, hemorrhage, and disseminated intravascular coagulation [16]. The clinical severity depends on serovar virulence, infectious dose, host immune status, and concurrent organ function [17].

Clinical Presentation

The incubation period in dogs ranges from 2 to 12 days [18]. Clinical signs are highly variable, ranging from subclinical infection to fulminant multisystemic disease. Classic signs include fever (often pyrexia >39.5 degrees Celsius), lethargy, anorexia, vomiting, abdominal pain, and polydipsia/polyuria [19, 20]. Icterus is observed in cases with severe hepatic involvement, often associated with serovars Icterohaemorrhagiae and Grippotyphosa [21]. Oliguric or anuric acute kidney injury (AKI) is the most common life-threatening manifestation, with azotemia, proteinuria, and granular casts on urinalysis [22]. Atypical presentations include pulmonary hemorrhage syndrome (dyspnea, hemoptysis) due to leptospiral-induced pulmonary capillaritis [23], and ocular signs such as uveitis and conjunctival suffusion [24]. Coagulopathies manifest as petechiae, epistaxis, and gastrointestinal bleeding [25].

The differential diagnosis includes canine parvovirus (see Canine Parvovirus Variants: CPV-2a, CPV-2b, and CPV-2c), Canine Distemper Virus Neurologic Disease, hepatic failure from toxic insults (e.g., xylitol, aflatoxin), and immune-mediated hemolytic anemia. A thorough history of environmental exposure (standing water, wildlife contact, kennel housing) increases suspicion.

Serovar Epidemiology

The distribution of pathogenic serovars in canine populations varies markedly by geographic region, climate, and urban versus rural setting. Based on a synthesis of cross-sectional serosurveys and culture-based studies [26, 27, 28, 29, 30], the following table summarizes the most commonly reported serovars affecting dogs globally.

Recent epidemiological studies have documented an increase in the proportion of serovars Grippotyphosa and Pomona relative to Canicola and Icterohaemorrhagiae, particularly in the United States and Canada [31, 32]. This shift has been attributed to changes in wildlife reservoir populations and the widespread use of bivalent vaccines historically covering only Canicola and Icterohaemorrhagiae [33]. In Europe, serovars Bratislava and Australis have been identified with growing frequency, especially in hunting dogs and those with access to peri-urban forest habitats [34].

Diagnostic Strategies

Microscopic Agglutination Test (MAT)

The MAT remains the reference standard for serological diagnosis of leptospirosis and is the most widely used test for population serosurveys [35]. The assay measures agglutinating antibodies (primarily IgM and IgG) against a panel of live or formalinized leptospiral serovars representative of local epidemiology. A fourfold rise in titer between acute and convalescent (2 to 4 weeks apart) samples is considered diagnostic. A single titer of 1:800 or higher in a clinically ill, unvaccinated dog is supportive of recent infection [36].

Limitations of MAT include:

• Poor sensitivity during the first week of illness due to delayed seroconversion.
• Inability to distinguish between vaccine-induced and infection-derived antibodies.
• Cross-reactivity between serogroups, leading to serovar misinterpretation.
• Requirement for live antigen cultures, which limits availability outside reference laboratories.
• Interlaboratory variability in antigen panels and cutoff thresholds.

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA-based methods can detect IgM and IgG antibodies separately. IgM detection improves early sensitivity and is particularly useful for acute-phase diagnostics [37]. Commercial ELISA kits have demonstrated moderate to high concordance with MAT and avoid the need for live cultures [38]. However, they do not provide serovar-level discrimination. The application of ELISA for Feline Leukemia Virus diagnostics is established in other fields, but its role in leptospirosis is primarily as a screening tool.

Real-Time PCR (qPCR)

Real-time PCR targeting the 16S rRNA gene or the lipL32 gene enables early detection of leptospiral DNA in blood, urine, cerebrospinal fluid, or tissue specimens before seroconversion [39]. LipL32 is a conserved outer membrane lipoprotein expressed only by pathogenic species, providing high specificity [40]. Whole blood samples are most sensitive during the first 4 to 7 days of clinical signs, whereas urine PCR becomes positive when renal colonization and shedding occur, typically from 4 to 10 days after infection, and can remain positive for weeks [41].

Advantages of qPCR include:

• Detection of infection independent of immune response, allowing diagnosis at initial presentation.
• Distinction between pathogenic and saprophytic species using species-specific probes.
• High sensitivity (reported >90%) in acute blood samples.
• Reduced turnaround time (2 to 4 hours) compared to MAT (days).

Limitations include the inability to determine serovar and the requirement for specialized thermocycling equipment and trained personnel. Multiplex PCR panels are increasingly used to simultaneously detect multiple pathogens causing acute febrile illness in dogs, such as Canine Coronavirus Variants and Canine Adenovirus 1 [42].

Point-of-Care Immunochromatographic Assays

Rapid immunochromatographic tests (ICTs) for detection of anti-Leptospira IgM have been developed for field and clinic use. These lateral-flow devices require no laboratory infrastructure and provide results within 15 to 20 minutes [43]. Sensitivity ranges from 70% to 85% compared to MAT in clinical cases, with specificity above 90% [44]. However, false positives due to vaccination and cross-reactive antibodies remain a concern. ICTs are best suited as rule-in tests in endemic settings with a high pretest probability.

Culture and Dark-Field Microscopy

Culture of leptospires from blood, urine, or tissues on Ellinghausen-McCullough-Johnson-Harris (EMJH) medium is the gold standard for definitive serovar identification, but it is impractical for routine diagnostics due to slow growth (weeks to months) and a low isolation rate (<20% of suspected cases) [45]. Dark-field microscopy of fresh urine or blood is highly operator dependent and suffers from low sensitivity and specificity.

Diagnostic Algorithm

The following Mermaid diagram represents a structured diagnostic workflow for a suspected canine leptospirosis case.

flowchart TD
    A["Suspected acute leptospirosis<br>(history of exposure, fever, AKI, icterus)"], > B["Blood collection<br>(EDTA + serum)"]
    B, > C{"Duration of signs"}
    C, >|< 7 days| D["qPCR on blood<br>(+/- urine)"]
    C, >|>= 7 days| E["Serology: MAT or IgM ELISA<br>(acute sample)"]
    D, > F{"qPCR result"}
    F, >|Positive| G["Confirm diagnosis.<br>Begin antibiotics and supportive care."]
    F, >|Negative| H{"Strong clinical suspicion?"}
    H, >|Yes| E
    H, >|No| I["Reassess for other causes<br>(parvovirus, distemper, toxins)"]
    E, > J{"MAT titer >= 1:800<br>or positive IgM ELISA"}
    J, >|Positive| G
    J, >|Negative| K["Collect convalescent serum<br>in 2-4 weeks"]
    K, > L["Repeat MAT or ELISA"]
    L, >|Fourfold rise| G
    L, >|No rise| I
    G, > M["Monitor renal function,<br>urine output, coagulation"]
    M, > N["Discontinue antibiotics after 14 days.<br>Recheck urine PCR at 4 weeks"]

Vaccination Strategies

Vaccination is the cornerstone of disease prevention in endemic regions. Inactivated whole-cell bacterins have been used for decades, providing serovar-specific protection by inducing anti-LPS antibodies that opsonize leptospires for phagocytosis and prevent renal colonization [46]. Traditional bivalent vaccines cover serovars Canicola and Icterohaemorrhagiae, but the changing epidemiology has driven the development of quadrivalent products that also include serovars Grippotyphosa and Pomona [47].

Vaccination does not prevent infection with heterologous serovars, and breakthrough infections in vaccinated animals are increasingly documented [48]. The duration of immunity is relatively short, requiring annual or semiannual boosters. Adverse reactions, including anaphylaxis in a small subset of dogs, are more frequent with leptospiral bacterins compared to core vaccines, necessitating careful monitoring [49]. Revaccination protocols that limit unnecessary antigenic stimulation have been proposed, including the use of serovar-specific titer determinations, although the correlation between antibody titer and protection is imperfect.

Adjuvanted subunit vaccines incorporating recombinant LipL32 or other conserved antigens are under investigation to broaden cross-protection and reduce adverse event profiles [50]. Until such products reach the market, annual quadrivalent vaccination remains the standard of care in endemic areas, particularly for dogs with outdoor access, hunting or farm exposure, and those housed in kennels.

Conclusion

Canine leptospirosis remains an important clinical entity with a complex interplay of host, pathogen, and environmental factors. The increasing recognition of non-traditional serovars such as Grippotyphosa and Pomona necessitates ongoing surveillance and diagnostic adaptability. Molecular diagnostics, particularly real-time PCR, offer significant advantages over MAT for early detection, but serology retains a vital role for retrospective confirmation and epidemiological monitoring. The development of rapid point-of-care immunoassays facilitates timely clinical decision-making, although their limitations must be weighed against context. Vaccination strategies must evolve to match the current serovar landscape, and future efforts should focus on universal vaccine platforms. A One Health approach that incorporates wildlife reservoir management, environmental hygiene, and canine vaccination is essential to reduce the burden of leptospirosis in both animal and human populations.

References

[1] Author A, Author B. Leptospirosis in dogs: a global perspective. Journal of Veterinary Internal Medicine.

[2] Author C, Author D. Clinical and pathological features of canine leptospirosis. Veterinary Pathology.

[3] Author E, Author F. Shifting serovar prevalence in North American canine populations. Journal of Veterinary Diagnostic Investigation.

[4] Author G, Author H. Expanding geographic range of Leptospira serovars. Emerging Infectious Diseases.

[5] Author I, Author J. Real-time PCR for detection of Leptospira in canine blood. Journal of Clinical Microbiology.

[6] Author K, Author L. Point-of-care immunochromatographic tests for canine leptospirosis. Veterinary Record.

[7] Author M, Author N. Serovar classification of pathogenic Leptospira. Microbiological Reviews.

[8] Author O, Author P. Leptospiral outer membrane proteins and host cell adhesion. Infection and Immunity.

[9] Author Q, Author R. Lipopolysaccharide structure in Leptospira interrogans. Molecular Microbiology.

[10] Author S, Author T. Complement evasion by pathogenic Leptospira. Frontiers in Immunology.

[11] Author U, Author V. Factor H binding in leptospiral pathogenesis. Journal of Infectious Diseases.

[12] Author W, Author X. Renal tubular colonization by Leptospira. Kidney International.

[13] Author Y, Author Z. Urinary shedding of leptospires in recovered dogs. American Journal of Veterinary Research.

[14] Author AA, Author BB. TLR2 and TLR4 signaling in leptospiral infection. Proceedings of the National Academy of Sciences.

[15] Author CC, Author DD. Cytokine profiles in canine leptospirosis. Veterinary Immunology and Immunopathology.

[16] Author EE, Author FF. Endothelial injury and coagulopathy in leptospirosis. Thrombosis and Haemostasis.

[17] Author GG, Author HH. Virulence factors of Leptospira interrogans. Trends in Microbiology.

[18] Author II, Author JJ. Experimental canine leptospirosis: incubation and pathogenesis. Journal of Comparative Pathology.

[19] Author KK, Author LL. Clinical signs of acute leptospirosis in dogs. Journal of the American Veterinary Medical Association.

[20] Author MM, Author NN. Fever patterns in canine leptospirosis. Veterinary Clinical Pathology.

[21] Author OO, Author PP. Icterus associated with serovars Icterohaemorrhagiae and Grippotyphosa. Journal of Veterinary Emergency and Critical Care.

[22] Author QQ, Author RR. Acute kidney injury in canine leptospirosis: a case series. Journal of Veterinary Internal Medicine.

[23] Author SS, Author TT. Pulmonary hemorrhage syndrome in dogs with leptospirosis. Veterinary Radiology and Ultrasound.

[24] Author UU, Author VV. Ocular manifestations of leptospirosis in dogs. Veterinary Ophthalmology.

[25] Author WW, Author XX. Coagulation abnormalities in canine leptospirosis. Journal of Veterinary Emergency and Critical Care.

[26] Author YY, Author ZZ. Cross-sectional serosurvey of Leptospira serovars in dogs. Preventive Veterinary Medicine.

[27] Author AAA, Author BBB. Culture-based isolation of Leptospira from canine urine. Journal of Clinical Microbiology.

[28] Author CCC, Author DDD. Serovars Grippotyphosa and Pomona in Midwestern dogs. Vector-Borne and Zoonotic Diseases.

[29] Author EEE, Author FFF. Urban rat reservoir and canine leptospirosis. PLoS Neglected Tropical Diseases.

[30] Author GGG, Author HHH. Emerging serovars in European canine populations. Veterinary Record.

[31] Author III, Author JJJ. Increase in non-traditional serovars in the United States. Journal of the American Veterinary Medical Association.

[32] Author KKK, Author LLL. Seroprevalence of Leptospira serovars in Canadian dogs. Canadian Veterinary Journal.

[33] Author MMM, Author NNN. Effect of bivalent vaccination on serovar distribution. Vaccine.

[34] Author OOO, Author PPP. Bratislava and Australis serovars in European hunting dogs. Journal of Wildlife Diseases.

[35] Author QQQ, Author RRR. Microscopic agglutination test: standardization and interpretation. Clinical and Vaccine Immunology.

[36] Author SSS, Author TTT. MAT titer interpretation in vaccinated vs. infected dogs. Journal of Veterinary Diagnostic Investigation.

[37] Author UUU, Author VVV. IgM ELISA for acute canine leptospirosis. Veterinary Microbiology.

[38] Author WWW, Author XXX. Comparison of commercial ELISA kits with MAT. Journal of Veterinary Diagnostic Investigation.

[39] Author YYY, Author ZZZ. LipL32 real-time PCR for early diagnosis. Journal of Clinical Microbiology.

[40] Author AAAA, Author BBBB. Specificity of LipL32 for pathogenic Leptospira. Infection and Immunity.

[41] Author CCCC, Author DDDD. Kinetics of leptospiral DNA in blood and urine. Journal of Veterinary Internal Medicine.

[42] Author EEEE, Author FFFF. Multiplex PCR for canine febrile illness. Veterinary Clinical Pathology.

[43] Author GGGG, Author HHHH. Lateral-flow immunoassay for leptospirosis. Journal of Medical Microbiology.

[44] Author IIII, Author JJJJ. Sensitivity and specificity of immunochromatographic tests. PLoS One.

[45] Author KKKK, Author LLLL. Culture isolation of Leptospira from clinical specimens. American Journal of Veterinary Research.

[46] Author MMMM, Author NNNN. Mechanism of protection by leptospiral bacterins. Vaccine.

[47] Author OOOO, Author PPPP. Quadrivalent vaccine performance in endemic areas. Journal of Veterinary Internal Medicine.

[48] Author QQQQ, Author RRRR. Breakthrough leptospirosis in vaccinated dogs. Journal of the American Veterinary Medical Association.

[49] Author SSSS, Author TTTT. Adverse reactions to leptospiral vaccines. Veterinary Dermatology.

[50] Author UUUU, Author VVVV. Recombinant LipL32 vaccine candidates. Veterinary Microbiology.